TABLE 5.

Models summarizing effects of contributing CCR2-CCR5 haplotypes or genotypes on HIV-1 RNA level during the first 3.5 years after seroconversion and on subsequent disease progression in MACS Caucasians

CCR genotype (no. of subjects)	Mean HIV-1 RNA concna at interval:								Survival (time to AIDS) analysis
	<6 mo (4.1)b	Pc	6–18 mo (12.5)b	Pc	19–30 mo (23.7)b	Pc	31–42 mo (36.2)b	Pc	RHe of AIDS	Pc
Model 1
F*2, no G*2 (60)	4.12	0.07	4.24	0.12	4.13	0.31	4.43	0.59	0.86	0.52
G*2, no F*2 (57)	4.22	0.24	4.09	0.01	4.16	0.08	4.18	0.61	0.77	0.24
F*2/G*2 (9)	4.11	0.32	3.46	0.001	3.42	0.001	3.75	0.10	0.45	0.18
E/E (39)	4.57	0.27	4.57	0.15	4.53	0.47	4.62	0.02	1.30	0.27
Others/reference (158)	4.39		4.38		4.39		4.20		Reference
Model Pd	0.04		0.0004		0.004		0.05		0.23 (PLR)	0.10f (Pw)
Model 2
F*2, no G*2 (60)	4.12	0.10	4.24	0.20	4.13	0.42	4.43	0.61	0.88	0.56
A/G*2 (11)	3.89	0.14	3.70	0.004	3.54	0.05	3.82	0.03	0.26	0.06
F*2/G*2 (9)	4.11	0.35	3.46	0.001	3.42	0.0004	3.75	0.09	0.46	0.19
E/E (39)	4.57	0.21	4.57	0.08	4.53	0.35	4.62	0.02	1.32	0.24
Others/Reference (213)	4.37		4.34		4.36		4.22		Reference
Model Pd	0.03		0.0001		0.003		0.01		0.08 (PLR)	0.03f (Pw)

^aExpressed as mean log₁₀ plasma HIV-1 RNA (copies/ml) based on ≥1 measurement available within each interval. The number of subjects differs between intervals, as shown in Table 1.

^bRange (median) of time interval between estimated date of seroconversion and median date of HIV RNA assay.

^cP values based on pairwise comparison between marker and reference (others) groups.

^dOverall P values based on multivariable analysis with GLMs.

^eRH according to cumulative proportion of those who develop AIDS over time with a CCR marker relative to those without it.

^fLog-rank (P_LR) and Wilcoxon (P_W) p values for AIDS-free time by Kaplan-Meier and Cox proportional hazards test (see text and Fig. 2).